Background-Clinical studies failed to provide clear evidence for a proatherogenic role of hypercoagulability. This is in contrast to the well-established detrimental role of hypercoagulability and thrombin during acute atherosclerotic complications. These seemingly opposing data suggest that hypercoagulability might exert both proatherogenic and antiatherogenic effects. We therefore investigated whether hypercoagulability mediates a beneficial effect during de novo atherogenesis. Methods and Results-De novo atherogenesis was evaluated in 2 mouse models with hyperlipidemia and genetically imposed hypercoagulability (TM Pro/Pro ApoE Ϫ/Ϫ and FVL Q/Q ApoE Ϫ/Ϫ mice). In both mouse models, hypercoagulability resulted in larger plaques, but vascular stenosis was not enhanced secondary to positive vascular remodeling. Importantly, plaque stability was increased in hypercoagulable mice with less necrotic cores, more extracellular matrix, more smooth muscle cells, and fewer macrophages. Long-term anticoagulation reversed these changes. The reduced frequency of intraplaque macrophages in hypercoagulable mice is explained by an inhibitory role of thrombin and protease-activated receptor-1 on monocyte transendothelial migration in vitro. This is dependent on phospholipase-C␤, phosphoinositide 3-kinase, and nitric oxide signaling in monocytes but not in endothelial cells. Conclusions-Here, we show a new function of the coagulation system, averting stenosis and plaque destabilization during de novo atherogenesis. The in vivo and in vitro data establish that thrombin-induced signaling via protease-activated receptor-1, phospholipase-C␤, phosphoinositide 3-kinase, and nitric oxide in monocytes impairs monocyte transendothelial migration. This likely accounts for the reduced macrophage accumulation in plaques of hypercoagulable mice. Thus, in contrast to their role in unstable plaques or after vascular injury, hypercoagulability and thrombin convey a protective effect during de novo atherogenesis. (Circulation. 2009;120:774-784.)
A therosclerosis is a slowly progressive disease characterized by vascular remodeling and intraplaque accumulation of monocyte-derived macrophages. The role of thrombin and the protease-activated receptor-1 (PAR-1) in atherosclerosis is generally perceived as being detrimental on the basis of their pathogenic role in acute atherosclerotic complications or after vascular injury. [1] [2] [3] This perception is fostered by a study evaluating de novo atherogenesis in experimental murine atherosclerosis, which showed larger plaques in hypercoagulable factor V Leiden mice (FVL Q/Q ). 4 However, several large studies evaluating the role of genetic risk factors of hypercoagulability (eg, factor V Leiden [FV G1691A] or prothrombin variant [FII G20210A]) failed to show an association between hypercoagulability and the prevalence of atherosclerosis, [5] [6] [7] [8] [9] suggesting that hypercoagulability does not promote the establishment of atherosclerotic disease. Thus, the role of hypercoagulability during de novo atherogenesis leading to atherosclerotic plaques remains undefined. From these data, we hypothesized that during de novo atherogenesis, hypercoagulability mediates a beneficial effect, which compensates for larger plaques. This beneficial effect would be in contrast to the detrimental consequences of hypercoagulability during acute vascular complications or after vascular injury.
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To explore the role of hypercoagulability during de novo atherogenesis, we used 2 mouse models with genetically increased coagulation activation: mice carrying the factor V Leiden (FVL Q/Q ) mutation resulting in hypercoagulability secondary to activated protein C (PC, encoded by Proc) resistance 4 and mice expressing a thrombomodulin (TM, encoded by Thbd) mutant resulting in hypercoagulability secondary to impaired PC activation (TM Pro/Pro mice). 10 These mouse strains were crossed with apolipoprotein E-deficient mice (ApoE
Ϫ/Ϫ
) and placed on a high-fat diet (HFD). Hypercoagulability in both mouse models resulted in larger plaques but not increased stenosis secondary to augmented positive vascular remodeling and in enhanced plaque stability. Thrombinenhanced plaque stability was mediated in part via phospholipase-C␤-(PLC␤), phosphoinositide 3-kinase-(PI3K), and nitric oxide-(NO) dependent signaling in monocytes but not in endothelial cells. These results identify a new function of the coagulation system, resulting in enhanced plaque stability during de novo atherogenesis.
Methods

Materials
See the Materials section in the online-only Data Supplement for details.
Mice
TM
Pro/Pro and FVL Q/Q mice have been described previously, 4, 10 and ApoE-deficient mice were obtained from the Jackson Laboratory (Bar Harbor, Me). Littermates were used with at least 98% of the genetic C57BL/6 background. Only female mice were used throughout this study. Mice (age, 6 to 8 weeks) received either a normal chow diet (controls) or an HFD. A subset of the HFD-fed mice received low-molecular-weight heparin (LMWH; enoxaparin 4 g/g body weight) subcutaneously once per day from the first day of the diet until 1 day before analyses. After 20 weeks of treatment, body weight was measured and mice were killed. Blood samples were obtained, and mice were perfused with ice-cold PBS (see the Materials section in the online-only Data Supplement).
Analysis of Blood Coagulation and Blood Lipids
Thrombin-antithrombin complexes (TAT) were determined with commercially available ELISAs that recognized mouse TAT. 11 Blood lipids were measured with the Advia 2400 Chemistry System from Roche (Basel, Switzerland).
Histology and Immunohistochemistry
Thoracic aortae were stained with Oil Red O. MOVATs stain was performed on frozen sections of brachiocephalic arteries. Samples were analyzed by a blinded investigator using the Image Pro Plus software (see the Materials section and Figure VI in the online-only Data Supplement).
Reverse-Transcriptase Polymerase Chain Reaction
Reverse-transcriptase polymerase chain reaction was performed as previously described (see the Materials section in the online-only Data Supplement).
Plasmid Preparation and Transfection of SVEC4 -10 Cells
For in vitro analyses, expression constructs containing either the sequence of wild-type (TM wt ) TM or a TM mutant with the Glu387Pro mutation (TM Pro ) were generated. The TM wt or TM Pro sequence was isolated with KpnI (blunted) and NotI from previously described vectors and subcloned into the expression vector pIRESneo3 (HpaI, NotI). SVEC4 -10 cells were transfected with HiFect.
In Vitro Proliferation, Apoptosis, and Transmigration Assay
Proliferation of THP-1 cells was determined by quantification of 3 H thymidine incorporation. Apoptosis was determined by staining of THP-1 cells with Annexin-V-Fluos and Propidiumiodide. Transmigration assay was performed as previously described (see the Materials section in the online-only Data Supplement).
Measurement of Nitrite Concentration and Quantification of Cell Shape
The stable NO metabolites nitrite and nitrate were measured by a microplate assay (colorimetric nitrite assay kit) according to the manufacturer's instructions. Cell area was determined after hematoxylin and eosin staining using random images (nϭ10 per well; NIS-Elements AR 2.30 software; see the Materials section in the online-only Data Supplement).
Isolation and Purification of Mouse Peripheral Blood Monocytes
Monocytes were isolated using a Ficoll gradient and were enriched by adhesion to plastic dishes. Enrichment for monocytes was confirmed by flow cytometry analyses (see the Materials section in the online-only Data Supplement).
Statistical Analysis
Female mice were grouped according to genotype and randomly assigned to different interventions (control diet, HFD, HFD plus heparin). All in vitro experiments were performed at least 3 times in replicates. Data The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Loss of Endothelial TM Function and Hypercoagulability in Hyperlipidemic Mice
Expression of TM in murine blood vessels was determined with immunohistochemistry. Expression of TM was reduced in TM 
ApoE
Ϫ/Ϫ C mice was associated with increased plasma TAT levels and reduced PC activation in vivo ( Figure 1C and 1D) , demonstrating blood coagulation activation and a loss of endothelial TM-dependent PC activation in hyperlipidemic mice. The loss of TM expression raises the question of whether impaired TM function and hypercoagulability modulate de novo atherogenesis.
To Figure 1E ).
Partial Loss of TM Function Increases Plaque Size but Not Vascular Stenosis in Hyperlipidemic Mice
Only small plaques were observed in a subset of TM wt ApoE Ϫ/Ϫ and TM Pro/Pro ApoE Ϫ/Ϫ mice on a normal chow diet, precluding detailed histological analyses (Figure 2A 
Anticoagulation Reduces Plaque Size
To explore to what extent the increased plaque size in TM Pro/Pro ApoE Ϫ/Ϫ HFD mice can be attributed to enhanced coagulation activation, mice were anticoagulated for the entire study period (20 weeks) with LMWH. 12 Figure 2E ). The reduction in plaque size after anticoagulation without a reduction in plasma lipid levels or lipid deposition within plaques ( Figure  2D ) is consistent with a role for the coagulation system in plaque development that is independent of intraplaque lipid accumulation. Figure  3A ). In TM Pro/Pro ApoE Ϫ/Ϫ HFD mice, the minimal thickness of the fibrous cap was significantly increased (12.5 versus 8.2 m; Pϭ0.047; Figure 3B ), unstable shoulder regions were less frequent (13% versus 92%; Pϭ0.016; Figure 3C ), extracellular matrix deposition in plaques was significantly increased (140ϫ10 3 versus 38ϫ10 3 m 2 ; PϽ0.001; Figure 3D ), and staining for fibrin was more pronounced (score of 3.0 versus 1.9 in TM wt ApoE Ϫ/Ϫ HFD mice; PϽ0.001; Figure 3E ). Plaque morphology and stability depend at least in part on the cellular components present within the plaque. In TM Pro/Pro ApoE Ϫ/Ϫ HFD mice, the plaque area staining positive for the macrophage marker Mac-2 was significantly smaller (6.3% versus 11.9%; Pϭ0.013; Figure 3F) Figure 3A ), the fibrous cap thickness decreased (8.1 versus 12.5 m; Pϭ0.032; Figure 3B ), the frequency of ruptured shoulders increased (80% versus 13%; Pϭ0.032; Figure 3C ), and extracellular matrix deposition decreased (66ϫ10 3 versus 140ϫ10 3 m 2 ; PϽ0.001; Figure  3D ). These changes in anticoagulated TM Pro/Pro ApoE Ϫ/Ϫ HFD mice were associated with increased staining for macrophages (12.0% versus 6.3%; Pϭ0.021; Figure 3F ) and reduced staining for SMCs within the plaques (score of 1.5 versus 2.3 in nonanticoagulated TM Pro/Pro ApoE Ϫ/Ϫ HFD mice, respectively; PϽ0.001; Figure 3G ). The reversibility of enhanced plaque stability in TM Pro/Pro ApoE Ϫ/Ϫ HFD mice after anticoagulation strongly suggests that hypercoagulability increases plaque stability. 
Larger but
Thrombin-Mediated PAR-1 Activation on Monocytes Reduces Transmigration
We next addressed potential mechanisms underlying the reduced frequency of macrophages within the plaques of hypercoagulable mice. On the basis of in vitro and ex vivo Figure 5A and data not shown).
To determine whether thrombin exerts its effect primarily on endothelial cells or monocytes, either HUVECs or THP-1 cells were pretreated with thrombin (10 nmol/L for 3 hours). Pretreatment of HUVECs with thrombin had no effect (248% versus 260%; Pϭ0.980; Figure 5A ), whereas pretreatment of THP-1 cells with thrombin significantly reduced MCP-1-induced transendothelial migration of THP-1 (to 120.2%; Pϭ0.004; Figure 5A ).
To evaluate whether the targeted point mutation of TM in TM Pro/Pro mice alters transendothelial migration of monocytes, we used the murine endothelial cell line SVEC4 -10, which does not express TM ( Figure II Figure 5B ). These results establish that reduced monocyte transmigration is independent of a direct effect of endothelial TM; rather, it is a consequence of enhanced thrombin formation and the effect of thrombin on monocytes.
We next investigated the role of thrombin-dependent activation of PARs. Pretreatment of THP-1 or J774A.1 cells, which strongly express PAR-1 and PAR-4 ( Figure III of the online-only Data Supplement), with thrombin receptor-activating peptide-1 (TRAP-1) reduced transmigration of monocytes ( Figure 5C and Figure IVA of the online-only Data Supplement), whereas other TRAPs (TRAP-2, -3, and -4) had no effect. Inhibiting PAR-1 activation with a blocking antibody (ATAP-2) abolished the inhibitory effect of thrombin ( Figure 5C ). Thus, monocyte transendothelial migration is reduced through a PAR-1-dependent mechanism in monocytes.
Thrombin Reduces Migration via Monocyte-Derived NO
To further identify the intracellular signaling pathway involved, we inhibited G␣i, PLC-␤ (which is downstream of G␣q), ROCK (which is downstream of G␣ 12/13 ), and PI3K. Pretreatment of THP-1 cells with pertussis toxin or with Y27632 did not alter the inhibitory effect of thrombin on transmigration ( Figure 5D ). Conversely, pretreatment with U73122 or with Ly-294002 abolished the inhibitory effect of thrombin ( Figure 5D ). Previous studies identified a role for thrombin in inhibiting monocyte activation through increased monocytic NO formation. 13 Preincubation of THP-1 cells with the NO synthase (NOS) inhibitor N G -nitro-L-arginine abolished the inhibitory effect of thrombin, whereas the NO donor S-nitroso-N-acetylpenicillamine had the same inhibitory effect as thrombin ( Figure 5D ). Consistent with these results, thrombin increased the production of NO, measured as the stable metabolite nitrite in the supernatant of THP-1 cells, through a PAR-1-and PLC␤/PI3K-dependent mechanism ( Figure 5E ). Thrombin-induced NO generation resulted in rounding of monocytes, indicating loss of pseudopodia formation and thus acquisition of a quiescent morphology ( Figure 5F ). Thus, thrombin inhibits transendothelial migration of monocytic cells in an autocrine or paracrine fashion by increasing monocytic NO generation through a PAR-1-dependent mechanism.
We next isolated primary monocytes from wild-type, TM Pro/Pro , and FVL Q/Q mice and determined transmigration of these cells through a SVEC4 -10 cell monolayer. Chemoattractant human complement factor 5a-induced transmigration of primary monocytes isolated from hypercoagulable TM Figure 5G ). Finally, emigration of monocytes into perivascular tissue of exteriorized cremaster muscles is impaired in hypercoagulable TM Pro/Pro mice ( Figure 5H ). These in vivo and ex vivo results are entirely consistent with the results obtained with THP-1 and J774A.1 cells in vitro, supporting the conclusion that thrombin reduces transendothelial migration of monocytes in hypercoagulable mice through PAR-1-, PLC␤-, PI3K-, and NO-dependent signaling in monocytes. These studies identify a new pathway through which hypercoagulability resulting in enhanced thrombin generation averts vascular stenosis and increases plaque stability during de novo atherogenesis.
Discussion
In contrast to the function of the coagulation system in vascular complications in acute atherosclerotic complications, the role of the coagulation system during de novo development of atherosclerotic plaques remained undefined. Clinical studies failed to provide clear evidence for a proatherogenic effect of hypercoagulability, 5-9 whereas in 1 study, larger plaques in hypercoagulable mice were demonstrated. 4 Using 2 distinct mouse models with hyperlipidemia and genetically imposed coagulation activation (TM Pro/Pro ApoE Ϫ/Ϫ and FVL Q/Q ApoE Ϫ/Ϫ mice), we showed that hypercoagulability results in larger plaques but not enhanced vascular stenosis secondary to positive vascular remodeling. Importantly, plaques in hypercoagulable mice were more stable with more extracellular matrix, more SMCs, and fewer macrophages, reflecting a plaque morphology typically associated with a reduced risk for acute vascular complications. 14 -16 These data identify a novel function of the coagulation system during atherogenesis. The protective effects of hypercoagulability during de novo atherogenesis compensate for the increased plaque size, thus providing a rationale for the paucity of epidemiological data showing an association between cardiovascular disease and genetic polymorphisms of hypercoagulability. [5] [6] [7] [8] [9] In the Atherosclerosis Risk in Communities (ARIC) study, in which a large number of hemostatic parameters were prospectively investigated, only the acute-phase proteins fibrinogen, factor VIII, and von Willebrand factor were independent positive predictors of coronary heart disease. 17 In the same study, an inverse correlation between coronary heart disease and soluble TM levels was observed. Originally, the high plasma levels of soluble TM and the associated reduced atherosclerosis risk were attributed to a higher expression level of endothelial TM at baseline. 18, 19 In view of the epidemiological data and our present results, we suggest that this conclusion requires reevaluation. We propose that high plasma levels of soluble TM do not reflect higher expression levels of endothelial TM but loss of endothelial TM, which is consistent with the established role of soluble plasma TM as a marker of endothelial dysfunction 12,20 -23 and a reduction in endothelial TM expression in human atherosclerotic blood vessels. 24 From these and the present data, we conclude that acquired hypercoagulability during atherogenesis, resulting in part from a loss of endothelial TM function, results in clinically more stable plaques.
What are the mechanisms through which hypercoagulability increases plaque stability during atherogenesis? The established proliferative effects of thrombin on SMCs and thrombin-dependent extracellular matrix synthesis likely contribute to the plaque-stabilizing effects without significantly enhancing stenosis. [25] [26] [27] [28] In addition to the proliferative effect of thrombin, fibrin and fibrin degradation products increase SMC proliferation. 29, 30 The increased fibrin deposition within the atherosclerotic plaques does not result from increased plasma fibrinogen levels, which is a typical finding in atherosclerotic patients, but is a consequence of hypercoagulability because (1) (3) an isolated elevation of fibrinogen plasma levels is not sufficient to alter plaque morphology during atherogenesis. 32 Thus, hypercoagulability, but not increased fibrinogen plasma levels, increases fibrin deposition within the plaques, contributing to increased plaque stability.
Besides augmenting SMCs and extracellular matrix content, hypercoagulability reduces the frequency of macrophages within the developing atherosclerotic plaque, which has stabilizing effects. Monocyte migration is inhibited by fibrin and fibrin-derived peptides, an effect that is enhanced after thrombin-induced ␣ and ␥ cross-linking. 33, 34 In addition, thrombin reduces monocyte migration via PAR-1-, PLC␤-, PI3K-, and NOS-dependent signaling in monocytic cells, an effect that is independent of endothelial cells. This finding is consistent with thrombin-dependent monocytic NO generation and NO-dependent inhibition of monocyte migration through ADP ribosylation of actin fibers. 13, 35, 36 An inhibitory effect of thrombin on monocyte activation, as observed in the present study, has been previously described. 13, 34, 37 In contrast to these and our results, other studies demonstrated a proinflammatory and promigratory effect of thrombin. 38, 39 However, in these 2 studies, the effect of thrombin on monocyte migration was evaluated in a setting of acute inflammation 38, 40 or by addressing a direct effect of thrombin on endothelial cells. 39 Models of acute inflammation evaluate the consequence of local and/or extravascular thrombin generation, whereas in the present study, the consequence of persistent but mild systemic intravascular hypercoagulability was addressed. The different results obtained in these studies suggest that the effects of thrombin are spatially different (local versus systemic). Spatially different effects of thrombin have been attributed to the local presence of adjuvant proinflammatory mediators at the site of acute inflammation. 38 It therefore appears that hypercoagulability and thrombin have different roles during atherosclerotic disease, with protective effects of systemic hypercoagulability during de novo atherogenesis and a detrimental synergistic effect of local thrombin generation and adjuvant proinflammatory mediators in unstable plaques and during acute complications of atherosclerotic disease. [41] [42] [43] During de novo atherogenesis, hypercoagulability dampens monocyte recruitment while increasing extracellular matrix synthesis and the number of SMCs, resulting in enhanced plaque stability and an increased vessel lumen. The increased vessel lumen compensates for larger plaques. Contrary to this, in the presence of adjuvant proinflammatory mediators, the enhanced monocyte recruitment, smooth muscle cell proliferation, and platelet activation worsen acute atherosclerotic disease and its complications. The opposing effects of hypercoagulability and thrombin compensate for each other, accounting for the lack of an association between hypercoagulability and atherosclerosis in clinical studies.
These findings provide new insight into the role of the coagulation system during atherogenesis. The present in vivo results are derived from murine models of hyperlipidemia and hypercoagulability, which is a potential limitation because atherosclerosis and the distribution and activation of PARs differ between humans and mice. Furthermore, future studies should evaluate the effect of other anticoagulants. Nevertheless, because the conclusion derived from the current in vivo studies is consistent with the results of epidemiological studies and because in vitro experiments with human and murine cells gave very similar results, we are confident that the conclusions are relevant to human disease. If confirmed in humans, these findings raise the question of how anticoagulation should be best achieved in patients at risk for both venous thrombosis and atherosclerosis. Targeting individual coagulation factors (eg, factor Xa), specifically fibrinogen, platelets, factor XII, and/or microparticles as recently suggested, 44 might be superior to nonspecific inhibition of the coagulation system (vitamin K antagonists, unfractionated heparin) in patients without or with minimal atherosclerotic disease.
